the mixture whereby a Form B crystalline polymorph that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately 10.7, 14.0, 16.4, 18.6, 22.1, and 26.4 is formed.

18. The pharmaceutical composition of claim 9 for use in the treatment of a hyperproliferative disorder selected from multiple myeloma, lymphoma, leukemias, prostate cancer, breast cancer, hepatocellular carcinoma, lunch cancer, pancreatic cancer, and colorectal cancer.

19. The use of a pharmaceutical composition of claim 9 for treating a hyperproliferative disorder selected from multiple myeloma, lymphoma, leukemias, prostate cancer, breast cancer, hepatocellular carcinoma, lunch cancer, pancreatic cancer, and colorectal cancer.

20. The use of a crystalline polymorph of any one of claims 1-8 as therapeutically active substance.

21. The crystalline polymorphs of any one of claims 1-8 for use in the treatment of a hyperproliferative disorder selected from multiple myeloma, lymphoma, leukemias, prostate cancer, breast cancer, hepatocellular carcinoma, lunch cancer, pancreatic cancer, and colorectal cancer.

22. The use of the crystalline polymorphs of any one of claims 1-8 in the treatment of a hyperproliferative disorder selected from multiple myeloma, lymphoma, leukemias, prostate cancer, breast cancer, hepatocellular carcinoma, lunch cancer, pancreatic cancer, and colorectal cancer.

23. The crystalline polymorphs of any one of claims 1-8 for use in the manufacture of a medicament for the treatment of a hyperproliferative disorder selected from multiple myeloma, lymphoma, leukemias, prostate cancer, breast cancer, hepatocellular carcinoma, lunch cancer, pancreatic cancer, and colorectal cancer.

~~24. The invention as hereinbefore described.~~